Engineered immune cells take on deadly brain cancer in first human test
NCT ID NCT06946680
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 20 times
Summary
This early-phase study tests whether a new type of immune cell therapy is safe and possible to make for people with aggressive brain tumors called high-grade gliomas. The therapy uses a patient's own immune cells, modified to recognize and attack tumor cells that carry a specific marker (CD70). The study involves 18 participants and focuses on finding the right dose and checking for severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida Health Children's Hospital
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.